Current Guidelines on the Management of Dyslipidemia.
10.24304/kjcp.2017.27.4.276
- Author:
Yunjeong CHOI
1
;
Song LEE
;
Ju Young KIM
;
Kyung Eun LEE
Author Information
1. College of Pharmacy, Chungbuk National University, Chungcheongbuk-do 28160, Republic of Korea. kaylee@cbnu.ac.kr
- Publication Type:Original Article
- Keywords:
Dyslipidemia;
cholesterol;
practice guideline;
disease management;
cardiovascular diseases
- From:Korean Journal of Clinical Pharmacy
2017;27(4):276-283
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: Dyslipidemia is recognized as a prominent risk factor for cardiovascular and cerebrovascular diseases but it is manageable through therapeutic and lifestyle intervention. Interpreting the latest guidelines is essential for an application of recommendation from guidelines into clinical practice. Therefore, this study aimed to compare the most recent guidelines on dyslipidemia treatment recommendations in Korea and USA. METHODS: This study analyzed and compared 2015 Korean guidelines for the management of dyslipidemia, 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline and 2016 supportive guidelines from ACC. RESULTS: A comparison was made focused on the following: target patients based on cardiovascular risk assessment, target goal, and treatment strategies including statin and non-statin therapies. Four target patient groups by risk were suggested in 2015 Korean guideline and cardiovascular risk factors were also considered for initiation of lipid lowering therapy. Titrated statin regimen was recommended by Korean guideline to reach LDL cholesterol and non-HDL cholesterol target level. In 2013 ACC/AHA guideline, four statin benefit group was introduced considering ASCVD risk and high intensity statin or intermediate intensity statin use were recommended without dose titration. 2016 update was to support non-statin therapy based on updated evidence and new consideration of ezetimibe, PCSK9-inhibitor and bile acid sequestrant was brought up. CONCLUSION: Guidelines are continuously updating as new and important clinical data are constantly released along with the advent of newly approved drugs for lipid disorder. This article provides resources that facilitates uptake of these recommendations into clinical practice.
